MERZ on the Move: Days After Ulthera Acquisition, Company Announces Plans for New Retinoid Therapy
Days after Ulthera acquisition, company announces plans to develop new Retinoid Therapy with Brickell Biotech.
Days after Ulthera acquisition, company announces plans to develop new Retinoid Therapy with Brickell Biotech.
The radiofrequency microneedling system uses a dual-depth approach to deliver energy across multiple skin layers, with companies reporting reduced treatment times and added safety features.